EcoAct has been supporting the Servier group since the beginning of its climate strategy. The pharmaceutical company wanted to step up its action in the fight against climate change and needed help to structure its greenhouse gas (GHG) emissions reduction trajectory.
Emitting more than 100,000 tCO2eq per year on its Scopes 1 and 2, the group wanted to have a better vision of the sector’s best practices in climate action, set a science-based target (SBT) and define a robust action plan to reduce its direct and indirect emissions (Scopes 1, 2 and 3) while being aligned with the Paris agreement.
Due to the diversity of its activities and its international supply chain, the real challenge was to obtain reliable data to measure the group’s carbon footprint by enabling all sites to monitor their GHG emissions reduction trajectory.
Servier is an international pharmaceutical laboratory run by a Foundation. With a solid presence in 150 countries and a turnover of €4.6 billion in 2019, Servier employs 22,000 people worldwide and is headquartered in Suresnes, France. Totally independent, the Group invests an average of 25% of its turnover (excluding generic activities) in Research and Development every year and uses all its profits for the benefit of its development. The Group’s growth is based on a strong commitment to five areas of excellence: cardiovascular, immuno-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as an activity in generic medicines; Servier also offers e-health solutions.